Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Preferred Stock Liabilities (2019 - 2020)

Historic Preferred Stock Liabilities for Pulmonx (LUNG) over the last 2 years, with Q3 2020 value amounting to $207.6 million.

  • Pulmonx's Preferred Stock Liabilities rose 110.06% to $207.6 million in Q3 2020 from the same period last year, while for Sep 2020 it was $207.6 million, marking a year-over-year increase of 110.06%. This contributed to the annual value of $205.3 million for FY2019, which is 4611.24% up from last year.
  • Per Pulmonx's latest filing, its Preferred Stock Liabilities stood at $207.6 million for Q3 2020, which was up 110.06% from $205.3 million recorded in Q4 2019.
  • Pulmonx's 5-year Preferred Stock Liabilities high stood at $207.6 million for Q3 2020, and its period low was $205.3 million during Q3 2019.